BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21947652)

  • 1. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.
    Wang C; Mayer JA; Mazumdar A; Brown PH
    Breast Cancer Res Treat; 2012 Jun; 133(2):487-500. PubMed ID: 21947652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer.
    Stine ZE; McGaughey DM; Bessling SL; Li S; McCallion AS
    Hum Mol Genet; 2011 Oct; 20(19):3746-56. PubMed ID: 21737465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).
    Kim DW; Chung HK; Park KC; Hwang JH; Jo YS; Chung J; Kalvakolanu DV; Resta N; Shong M
    Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
    Zou Y; Tsai WB; Cheng CJ; Hsu C; Chung YM; Li PC; Lin SH; Hu MC
    Breast Cancer Res; 2008; 10(1):R21. PubMed ID: 18312651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.
    Kim YR; Byun HS; Won M; Park KA; Kim JM; Choi BL; Lee H; Hong JH; Park J; Seok JH; Kim DW; Shong M; Park SK; Hur GM
    BMC Cancer; 2008 May; 8():144. PubMed ID: 18498667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor.
    Spanheimer PM; Woodfield GW; Cyr AR; Kulak MV; White-Baer LS; Bair TB; Weigel RJ
    Ann Surg Oncol; 2013 Jul; 20(7):2204-12. PubMed ID: 22878616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE).
    Wang C; Uray IP; Mazumdar A; Mayer JA; Brown PH
    Breast Cancer Res Treat; 2012 Jul; 134(1):101-15. PubMed ID: 22212555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor.
    Wang C; Mayer JA; Mazumdar A; Fertuck K; Kim H; Brown M; Brown PH
    Mol Endocrinol; 2011 Sep; 25(9):1527-38. PubMed ID: 21835891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
    Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
    Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.
    Boulay A; Breuleux M; Stephan C; Fux C; Brisken C; Fiche M; Wartmann M; Stumm M; Lane HA; Hynes NE
    Cancer Res; 2008 May; 68(10):3743-51. PubMed ID: 18483257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
    Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
    Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
    Weigel MT; Ghazoui Z; Dunbier A; Pancholi S; Dowsett M; Martin LA
    Breast Cancer Res; 2012 May; 14(3):R78. PubMed ID: 22608253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation.
    Hwang JH; Kim DW; Suh JM; Kim H; Song JH; Hwang ES; Park KC; Chung HK; Kim JM; Lee TH; Yu DY; Shong M
    Mol Endocrinol; 2003 Jun; 17(6):1155-66. PubMed ID: 12637586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ER-positive breast cancer cells are poised for RET-mediated endocrine resistance.
    Horibata S; Rice EJ; Mukai C; Marks BA; Sams K; Zheng H; Anguish LJ; Coonrod SA; Danko CG
    PLoS One; 2018; 13(4):e0194023. PubMed ID: 29608602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
    Ijichi N; Shigekawa T; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S
    Horm Cancer; 2012 Aug; 3(4):147-59. PubMed ID: 22476979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
    Sengupta S; Schiff R; Katzenellenbogen BS
    Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases.
    Jung HS; Kim DW; Jo YS; Chung HK; Song JH; Park JS; Park KC; Park SH; Hwang JH; Jo KW; Shong M
    Mol Endocrinol; 2005 Nov; 19(11):2748-59. PubMed ID: 15994200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive Breast Cancer Cells.
    Gadad SS; Camacho CV; Malladi V; Hutti CR; Nagari A; Kraus WL
    Mol Cancer Res; 2021 Oct; 19(10):1688-1698. PubMed ID: 34158394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.